We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CLSD market cap is 71.29M. The company's latest EPS is USD -0.4283 and P/E is -2.15.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.02M | 859k | 6.35M | 230k | 90k |
| Operating Income | -7.27M | -7.05M | -2.92M | -8.21M | -7.59M |
| Net Income | -9.11M | -9.27M | -4.83M | -11.76M | -7.59M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.17M | 7.89M | 29.58M | 1.33M | 8.23M |
| Operating Income | -30.3M | -17.94M | -627k | -30.28M | -24.84M |
| Net Income | -30.77M | -18.21M | 376k | -32.95M | -32.49M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 39.19M | 34.42M | 34.02M | 40.14M | 33.93M |
| Total Liabilities | 44.16M | 47.27M | 49.93M | 61.95M | 62.22M |
| Total Equity | -4.97M | -12.85M | -15.91M | -21.81M | -28.29M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 26.78M | 19.32M | 42.9M | 51.3M | 34.02M |
| Total Liabilities | 15.62M | 10.56M | 4.93M | 40.7M | 49.93M |
| Total Equity | 11.16M | 8.76M | 37.98M | 10.61M | -15.91M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -12.56M | -18.63M | -18.14M | -7.85M | -13.53M |
| Investing | -1.21M | -1.66M | -1.78M | -57k | -11.49M |
| Financing | 354k | 671k | 414k | 14.34M | 14.34M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -27.07M | -13.12M | -10.73M | -13.37M | -18.14M |
| Investing | 32.93M | -55k | N/A | -246k | -1.78M |
| Financing | 8.7M | 7.87M | 23.78M | 31.33M | 414k |
| Market Cap | 71.29M |
| Price to Earnings Ratio | -2.15 |
| Price to Sales Ratio | 8.48 |
| Price to Cash Ratio | 2.41 |
| Price to Book Ratio | -4.39 |
| Dividend Yield | - |
| Shares Outstanding | 75.84M |
| Average Volume (1 week) | 291.96k |
| Average Volume (1 Month) | 238.21k |
| 52 Week Change | -7.84% |
| 52 Week High | 2.12 |
| 52 Week Low | 0.92 |
| Spread (Intraday) | 0.07 (7.03%) |
| Company Name | Clearside Biomedical Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.clearsidebio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
